ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
위암 치료 시장 규모는 향후 수년간 강력한 성장이 전망됩니다. 2029년에는 연평균 성장률(CAGR) 9.1%로 63억 9,000만 달러로 성장합니다. 예측 기간의 성장은 바이오마커 기반 치료법의 부상, 병용 치료 전략 증가, 종양학 연구개발에 대한 투자 확대, 신흥 시장의 헬스케어 인프라 확대, 모니터링용 액체생검의 채택 등에 기인하는 것으로 분석됩니다. 이 기간 중 예상되는 주요 동향으로는 맞춤형 의료의 발전, 표적 약물전달 시스템의 중요성, 신규 항체 임상시험의 급증, 영상 진단에 AI의 통합, 병용 요법의 개발 등이 있습니다.
헬리코박터 파일로리 감염 유병률 증가는 향후 위암 치료제 시장의 성장을 촉진할 것으로 예측됩니다. 헬리코박터 파일로리균은 주로 위 점막을 침범하는 세균 감염으로 만성 위염과 위암의 주요 원인입니다. 헬리코박터 파일로리 감염 증가는 주로 불결한 위생 상태와 오염된 음식이나 물이 박테리아의 경구-경구 감염 또는 대변-경구 감염을 촉진하기 때문입니다. 위암 치료는 헬리코박터 파일로리균의 감염을 치료하고, 위의 염증과 세포 손상을 줄이며, 만성 위염과 위축성 변화로 인한 위 점막의 악화를 예방하여 헬리코박터 파일로리균으로 인한 위암의 위험을 낮춥니다. 예를 들어 2024년 11월 캐나다 정부가 발표한 보고서에 따르면 2023년 1월 현재 헬리코박터 파일로리균 감염 재발률은 지역과 연령에 따라 다르지만 최대 19%로 추정됩니다. 이처럼 헬리코박터 파일로리 감염의 유병률 증가는 위암 치료제 시장을 촉진하고 있습니다.
위암 치료 시장의 주요 기업은 치료 효과를 높이고 환자의 예후를 개선하기 위해 병용요법 등 혁신적인 치료법에 집중하고 있습니다. 병용요법은 화학요법, 표적치료, 면역요법 등 두 가지 이상의 치료법을 병용하여 전반적인 치료 효과를 높이는 것입니다. 2024년 12월, BeiGene으로 알려진 중국 제약회사 BeOne Medicines Ltd.는 절제불능 또는 전이성 HER2 음성 위 또는 위식도 접합부(G/GEJ) 선암에서 PD-L1을 발현하는(≥1) 성인 환자의 1차 치료제로 백금 제제 및 플루오로피리미딘 기반 화학요법과 병용하는 테빔브라(tislelizumab-jsgr)가 미국 식품의약국(FDA)의 승인을 획득했습니다. 이번 승인은 RATIONALE-305 임상 3상 시험 결과를 바탕으로 한 것으로, 이 병용요법은 화학요법 단독요법의 12.9개월 대비 중앙생존기간을 15.0개월로 개선하고 사망위험을 20% 감소시킨 것으로 나타났습니다. 이번 성과는 진행성 위암 환자의 임상결과를 개선하고 병세 진행을 지연시키며 생존기간을 연장하기 위해 기존 화학요법에 면역항암제를 결합한 다제 병용요법에 투자하는 제약사 증가 추세를 반영하는 것입니다.
목차
제1장 개요
제2장 시장의 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세 및 Covid와 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 위암 치료 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 용도 산업의 분석
세계의 위암 치료 시장 : 성장률 분석
세계의 위암 치료 시장 실적 : 규모와 성장, 2019-2024
세계의 위암 치료 시장 예측 : 규모와 성장, 2024-2029, 2034F
세계의 위암 치료 : TAM(Total Addressable Market)
제6장 시장 세분화
세계의 위암 치료 시장 : 치료 유형별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
화학요법
표적치료
면역치료
방사선 치료
수술
세계의 위암 치료 시장 : 약제 클래스별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
세포 상해성 약제
모노클로널 항체
티로신 키나아제 저해제
체크포인트 저해제
기타 에이전트
세계의 위암 치료 시장 : 투여 경로별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
경구
정맥내
근육내
피하
세계의 위암 치료 시장 : 질병 단계별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
조기
국소 진행 단계
전이 단계
세계의 위암 치료 시장 : 최종사용자별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
병원
종양학 클리닉
외래 수술 센터
조사기관
홈케어 설정
세계의 위암 치료 시장 : 서브 세분화, 화학요법(유형별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
수술전 화학요법(NAC)
보조 화학요법(AC)
완화 화학요법(PC)
병용 화학요법
단독요법
세계의 위암 치료 시장 : 서브 세분화, 표적치료(유형별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
인간 표피성장인자 수용체 2(HER2) 표적치료
혈관내피세포성장인자(VEGF) 저해제
섬유아세포 증식인자 수용체(FGFR) 저해제
간엽계 상피 전환(MET) 저해제
Claudin 18 Isoform 2 저해제
세계의 위암 치료 시장 : 서브 세분화, 면역치료(유형별), 실적과 예측, 2019-2024, 2024-2029F, 2034F
면역 체크포인트 저해제
암 백신
양자 세포 이식
사이토카인 요법
병용 면역치료
세계의 위암 치료 시장 : 서브 세분화, 방사선 요법의 유형, 실적과 예측, 2019-2024, 2024-2029F, 2034F
외부 방사선 치료(EBRT)
강도 변조 방사선 치료(IMRT)
3차원 원체 방사선 치료(3D-CRT)
근접 방사선 요법
세계의 위암 치료 시장 : 서브 세분화, 수술의 유형, 실적과 예측, 2019-2024, 2024-2029F, 2034F
내시경적 점막 절제술(EMR)
내시경적 점막 하층 박리술(ESD)
Subtotal Gastrectomy
Total Gastrectomy
Lymphadenectomy
제7장 지역별·국가별 분석
세계의 위암 치료 시장 : 지역별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
세계의 위암 치료 시장 : 국가별, 실적과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
위암 치료 시장 : 경쟁 구도
위암 치료 시장 : 기업 개요
Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
제31장 기타 대기업과 혁신적 기업
AstraZeneca PLC
Novartis AG
GSK plc
Eli Lilly and Company
Amgen Inc.
Teva Pharmaceutical Industries Ltd.
Otsuka Holdings Co. Ltd.
Astellas Pharma Inc.
Jiangsu Hengrui Pharmaceuticals Co. Ltd.
BeiGene Ltd.
Celltrion Healthcare Co. Ltd.
Hutchison MediPharma Limited
Shanghai Henlius Biotech Inc.
Imugene Limited
LintonPharm Co. Ltd.
제32장 세계의 시장 경쟁 벤치마킹과 대시보드
제33장 주요 합병과 인수
제34장 최근 시장 동향
제35장 시장 잠재력이 높은 국가, 부문, 전략
위암 치료 시장 2029 : 새로운 기회를 제공하는 국가
위암 치료 시장 2029 : 새로운 기회를 제공하는 부문
위암 치료 시장 2029 : 성장 전략
시장 동향에 기반한 전략
경쟁사 전략
제36장 부록
KSA
영문 목차
영문목차
Gastric cancer therapy encompasses the medical treatments aimed at managing and eradicating cancer that originates in the stomach lining. These treatments include surgery, chemotherapy, radiation therapy, targeted therapy, and immunotherapy, which may be used alone or in combination based on the disease's stage and specific characteristics. The therapies function by killing rapidly dividing cancer cells, blocking molecular pathways that promote tumor growth, or activating the immune system to target cancer cells.
The primary categories of gastric cancer therapy are chemotherapy, targeted therapy, immunotherapy, radiation therapy, and surgery. Chemotherapy uses drugs to destroy rapidly dividing cancer cells throughout the body. These drugs are grouped into cytotoxic agents, monoclonal antibodies, tyrosine kinase inhibitors, checkpoint inhibitors, and other miscellaneous agents and can be delivered orally, intravenously, intramuscularly, or subcutaneously. These therapies are employed across various disease stages-including early, locally advanced, and metastatic and are used by multiple end users such as hospitals, oncology clinics, ambulatory surgical centers, research facilities, and home care providers.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the pharmaceutical companies contend with tariffs on APIs, glass vials, and lab equipment inputs with few alternative sources. Generic drug makers, operating on razor-thin margins, are especially vulnerable, with some reducing production of low-profit medicines. Biotech firms face delays in clinical trials due to tariff-related shortages of specialized reagents. In response, the industry is expanding API production in India and Europe, increasing inventory stockpiles, and pushing for trade exemptions for essential medicines.
The gastric cancer therapy market research report is one of a series of new reports from The Business Research Company that provides gastric cancer therapy market statistics, including the gastric cancer therapy industry global market size, regional shares, competitors with the gastric cancer therapy market share, detailed gastric cancer therapy market segments, market trends, and opportunities, and any further data you may need to thrive in the gastric cancer therapy industry. These gastric cancer therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The gastric cancer therapy market size has grown strongly in recent years. It will grow from $4.12 billion in 2024 to $4.50 billion in 2025 at a compound annual growth rate (CAGR) of 9.3%. The growth during the historical period can be attributed to the rising prevalence of H. pylori infection, increased tobacco and alcohol use, an expanding aging population, limited availability of early diagnostic methods, and the broad adoption of chemotherapy.
The gastric cancer therapy market size is expected to see strong growth in the next few years. It will grow to $6.39 billion in 2029 at a compound annual growth rate (CAGR) of 9.1%. The projected growth in the forecast period can be attributed to the rise of biomarker-based therapies, an increase in combination treatment strategies, growing investment in oncology research and development, expansion of healthcare infrastructure in emerging markets, and the adoption of liquid biopsies for monitoring. Key trends expected during this period include advancements in personalized medicine, emphasis on targeted drug delivery systems, a surge in clinical trials for new antibodies, integration of AI in diagnostic imaging, and the development of combination therapies.
The increasing prevalence of Helicobacter pylori infection is expected to drive the growth of the gastric cancer therapy market in the future. Helicobacter pylori is a bacterial infection that primarily affects the stomach lining and is a major cause of chronic gastritis and gastric cancer. The rise in Helicobacter pylori infections is mainly attributed to poor sanitation, as inadequate hygiene and contaminated food or water promote oral-oral or fecal-oral transmission of the bacteria. Gastric cancer therapy helps lower the risk of gastric cancer caused by Helicobacter pylori by treating the infection, reducing gastric inflammation and cellular damage, and preventing the progression from chronic gastritis and atrophic changes to malignant transformation of the stomach lining. For example, a report published by the Government of Canada in November 2024 stated that as of January 2023, the recurrence rate of H. pylori infection is estimated to be up to 19%, although this varies depending on geographic location and age. Thus, the growing prevalence of Helicobacter pylori infection is propelling the gastric cancer therapy market.
Leading companies in the gastric cancer therapy market are focusing on innovative treatments such as combination therapy to enhance treatment effectiveness and improve patient outcomes. Combination therapy uses two or more treatments-such as chemotherapy, targeted therapy, or immunotherapy-together to increase overall efficacy. In December 2024, BeOne Medicines Ltd., a China-based pharmaceutical company formerly known as BeiGene, received U.S. Food and Drug Administration (FDA) approval for Tevimbra (tislelizumab-jsgr) combined with platinum- and fluoropyrimidine-based chemotherapy as a first-line treatment for adults with unresectable or metastatic HER2-negative gastric or gastroesophageal junction (G/GEJ) adenocarcinoma whose tumors express PD-L1 (>=1). This approval was based on the Phase 3 RATIONALE-305 trial, which showed that the combination therapy improved median overall survival to 15.0 months compared to 12.9 months with chemotherapy alone, representing a 20% reduction in the risk of death. This achievement reflects a growing trend among pharmaceutical companies to invest in multimodal treatments that combine immunotherapy with traditional chemotherapy to improve clinical results, delay disease progression, and extend survival in advanced gastric cancer patients.
In January 2023, Leap Therapeutics Inc., a U.S.-based biotechnology firm, acquired Flame Biosciences Inc. for an undisclosed amount. This acquisition aims to bolster Leap Therapeutics' oncology pipeline by adding Flame Biosciences' clinical-stage anti-Claudin18.2 antibody FL-301 and two preclinical antibody programs, advancing the development of biomarker-targeted cancer therapies. Flame Biosciences Inc. is a U.S.-based biotechnology company specializing in gastric cancer therapies.
Major players in the gastric cancer therapy market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GSK plc, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Otsuka Holdings Co. Ltd., Astellas Pharma Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., BeiGene Ltd., Celltrion Healthcare Co. Ltd., Hutchison MediPharma Limited, Shanghai Henlius Biotech Inc., Imugene Limited, and LintonPharm Co. Ltd.
North America was the largest region in the gastric cancer therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in gastric cancer therapy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the gastric cancer therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The gastric cancer therapy market consists of revenues earned by entities by providing services such as diagnostic testing and imaging, supportive care and palliative services, and clinical trial and research services. The market value includes the value of related goods sold by the service provider or included within the service offering. The gastric cancer therapy market also includes sales of trastuzumab (Herceptin), nivolumab (Opdivo), ramucirumab (Cyramza), and fluorouracil-based chemotherapy, and endoscopic devices and imaging systems. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Gastric Cancer Therapy Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on gastric cancer therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for gastric cancer therapy ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The gastric cancer therapy market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Therapy Type: Chemotherapy; Targeted Therapy; Immunotherapy; Radiation Therapy; Surgery
2) By Drug Class: Cytotoxic Agents; Monoclonal Antibodies; Tyrosine Kinase Inhibitors; Checkpoint Inhibitors; Miscellaneous Agents
3) By Administration Route: Oral; Intravenous; Intramuscular; Subcutaneous
4) By Stage of Disease: Early Stage; Locally Advanced Stage; Metastatic Stage
5) By End User: Hospitals; Oncology Clinics; Ambulatory Surgical Centers; Research Institutions; Home Care Settings
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Gastric Cancer Therapy Market Characteristics
3. Gastric Cancer Therapy Market Trends And Strategies
4. Gastric Cancer Therapy Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
5. Global Gastric Cancer Therapy Growth Analysis And Strategic Analysis Framework
5.1. Global Gastric Cancer Therapy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Gastric Cancer Therapy Market Growth Rate Analysis
5.4. Global Gastric Cancer Therapy Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Gastric Cancer Therapy Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Gastric Cancer Therapy Total Addressable Market (TAM)
6. Gastric Cancer Therapy Market Segmentation
6.1. Global Gastric Cancer Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Chemotherapy
Targeted Therapy
Immunotherapy
Radiation Therapy
Surgery
6.2. Global Gastric Cancer Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Cytotoxic Agents
Monoclonal Antibodies
Tyrosine Kinase Inhibitors
Checkpoint Inhibitors
Miscellaneous Agents
6.3. Global Gastric Cancer Therapy Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Intravenous
Intramuscular
Subcutaneous
6.4. Global Gastric Cancer Therapy Market, Segmentation By Stage of Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Early Stage
Locally Advanced Stage
Metastatic Stage
6.5. Global Gastric Cancer Therapy Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Oncology Clinics
Ambulatory Surgical Centers
Research Institutions
Home Care Settings
6.6. Global Gastric Cancer Therapy Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Neoadjuvant Chemotherapy (NAC)
Adjuvant Chemotherapy (AC)
Palliative Chemotherapy (PC)
Combination Chemotherapy
Monotherapy
6.7. Global Gastric Cancer Therapy Market, Sub-Segmentation Of Targeted Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Human Epidermal Growth Factor Receptor 2 (HER2) Targeted Therapy
6.8. Global Gastric Cancer Therapy Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Immune Checkpoint Inhibitors
Cancer Vaccines
Adoptive Cell Transfer
Cytokine Therapy
Combination Immunotherapy
6.9. Global Gastric Cancer Therapy Market, Sub-Segmentation Of Radiation Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
6.10. Global Gastric Cancer Therapy Market, Sub-Segmentation Of Surgery, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Endoscopic Mucosal Resection (EMR)
Endoscopic Submucosal Dissection (ESD)
Subtotal Gastrectomy
Total Gastrectomy
Lymphadenectomy
7. Gastric Cancer Therapy Market Regional And Country Analysis
7.1. Global Gastric Cancer Therapy Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Gastric Cancer Therapy Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Gastric Cancer Therapy Market
8.1. Asia-Pacific Gastric Cancer Therapy Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Gastric Cancer Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Gastric Cancer Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Gastric Cancer Therapy Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Gastric Cancer Therapy Market
9.1. China Gastric Cancer Therapy Market Overview
9.2. China Gastric Cancer Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Gastric Cancer Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Gastric Cancer Therapy Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Gastric Cancer Therapy Market
10.1. India Gastric Cancer Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Gastric Cancer Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Gastric Cancer Therapy Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Gastric Cancer Therapy Market
11.1. Japan Gastric Cancer Therapy Market Overview
11.2. Japan Gastric Cancer Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Gastric Cancer Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Gastric Cancer Therapy Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Gastric Cancer Therapy Market
12.1. Australia Gastric Cancer Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Gastric Cancer Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Gastric Cancer Therapy Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Gastric Cancer Therapy Market
13.1. Indonesia Gastric Cancer Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Gastric Cancer Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Gastric Cancer Therapy Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Gastric Cancer Therapy Market
14.1. South Korea Gastric Cancer Therapy Market Overview
14.2. South Korea Gastric Cancer Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Gastric Cancer Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Gastric Cancer Therapy Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Gastric Cancer Therapy Market
15.1. Western Europe Gastric Cancer Therapy Market Overview
15.2. Western Europe Gastric Cancer Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Gastric Cancer Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Gastric Cancer Therapy Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Gastric Cancer Therapy Market
16.1. UK Gastric Cancer Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Gastric Cancer Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Gastric Cancer Therapy Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Gastric Cancer Therapy Market
17.1. Germany Gastric Cancer Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Gastric Cancer Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Gastric Cancer Therapy Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Gastric Cancer Therapy Market
18.1. France Gastric Cancer Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Gastric Cancer Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Gastric Cancer Therapy Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Gastric Cancer Therapy Market
19.1. Italy Gastric Cancer Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Gastric Cancer Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Gastric Cancer Therapy Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Gastric Cancer Therapy Market
20.1. Spain Gastric Cancer Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Gastric Cancer Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Gastric Cancer Therapy Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Gastric Cancer Therapy Market
21.1. Eastern Europe Gastric Cancer Therapy Market Overview
21.2. Eastern Europe Gastric Cancer Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Gastric Cancer Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Gastric Cancer Therapy Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Gastric Cancer Therapy Market
22.1. Russia Gastric Cancer Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Gastric Cancer Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Gastric Cancer Therapy Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Gastric Cancer Therapy Market
23.1. North America Gastric Cancer Therapy Market Overview
23.2. North America Gastric Cancer Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Gastric Cancer Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Gastric Cancer Therapy Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Gastric Cancer Therapy Market
24.1. USA Gastric Cancer Therapy Market Overview
24.2. USA Gastric Cancer Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Gastric Cancer Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Gastric Cancer Therapy Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Gastric Cancer Therapy Market
25.1. Canada Gastric Cancer Therapy Market Overview
25.2. Canada Gastric Cancer Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Gastric Cancer Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Gastric Cancer Therapy Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Gastric Cancer Therapy Market
26.1. South America Gastric Cancer Therapy Market Overview
26.2. South America Gastric Cancer Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Gastric Cancer Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Gastric Cancer Therapy Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Gastric Cancer Therapy Market
27.1. Brazil Gastric Cancer Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Gastric Cancer Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Gastric Cancer Therapy Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Gastric Cancer Therapy Market
28.1. Middle East Gastric Cancer Therapy Market Overview
28.2. Middle East Gastric Cancer Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Gastric Cancer Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Gastric Cancer Therapy Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Gastric Cancer Therapy Market
29.1. Africa Gastric Cancer Therapy Market Overview
29.2. Africa Gastric Cancer Therapy Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Gastric Cancer Therapy Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Gastric Cancer Therapy Market, Segmentation By Administration Route, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Gastric Cancer Therapy Market Competitive Landscape And Company Profiles
30.1. Gastric Cancer Therapy Market Competitive Landscape
30.2. Gastric Cancer Therapy Market Company Profiles
30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.4. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
30.2.5. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
31. Gastric Cancer Therapy Market Other Major And Innovative Companies
31.1. AstraZeneca PLC
31.2. Novartis AG
31.3. GSK plc
31.4. Eli Lilly and Company
31.5. Amgen Inc.
31.6. Teva Pharmaceutical Industries Ltd.
31.7. Otsuka Holdings Co. Ltd.
31.8. Astellas Pharma Inc.
31.9. Jiangsu Hengrui Pharmaceuticals Co. Ltd.
31.10. BeiGene Ltd.
31.11. Celltrion Healthcare Co. Ltd.
31.12. Hutchison MediPharma Limited
31.13. Shanghai Henlius Biotech Inc.
31.14. Imugene Limited
31.15. LintonPharm Co. Ltd.
32. Global Gastric Cancer Therapy Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Gastric Cancer Therapy Market
34. Recent Developments In The Gastric Cancer Therapy Market
35. Gastric Cancer Therapy Market High Potential Countries, Segments and Strategies
35.1 Gastric Cancer Therapy Market In 2029 - Countries Offering Most New Opportunities
35.2 Gastric Cancer Therapy Market In 2029 - Segments Offering Most New Opportunities
35.3 Gastric Cancer Therapy Market In 2029 - Growth Strategies
